"Mast"ering drug discovery with iPSCs.

@article{Dorrance2021MasteringDD,
  title={"Mast"ering drug discovery with iPSCs.},
  author={Adrienne Dorrance},
  journal={Blood},
  year={2021},
  volume={137 15},
  pages={
          1993-1994
        }
}
2 Citations
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis
TLDR
Assessment of multilineage involvement of haematopoiesis by KIT D816V and additional mutations in genes known to be associated with the prognosis of SM have become of great help to identify good vs. poor-prognosis SM patients who could benefit from a closer follow-up and, eventually, also early cytoreductive treatment.
Precision Medicine in Systemic Mastocytosis
TLDR
The clinical, diagnostic, and therapeutic issues of SM are reviewed, with special emphasis on the translational implications of SM genetics for a precision medicine approach in clinical practice.

References

SHOWING 1-6 OF 6 REFERENCES
Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic Mastocytosis.
TLDR
This study identified nintedanib, an FDA approved angiokinase inhibitor that targets VEGFR, PDGFR and FGFR, as a novel KIT D816V inhibitor and suggested nintinganib as a new drug candidate for K IT D 816V targeted therapy of advanced SM.
New Developments in Diagnosis, Prognostication, and Treatment of Advanced Systemic Mastocytosis.
TLDR
Looking forward, perhaps the most fruitful marriage of the advances in molecular genetics and treatment will be the design of adaptive basket trials that combine histopathology and genetic profiling to individualize treatment approaches for patients with diverse AHNs and relapsed/refractory SM.
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.
TLDR
An overview of recent advances in the field of mastocytosis is provided, with emphasis on classification, prognostication, and emerging new treatment options in advanced systemic mastocyTosis.
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
TLDR
Data indicate that SM-AHNMD is a multi-mutated neoplasm, KIT D816V or other mutations are rare in CFU-GM colonies of ISM/SSM patients, which might explain at least in part their better prognosis.
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.
TLDR
An overview of recent developments in the field of mastocytosis is provided, with emphasis on the updated WHO classification, refined criteria, additional prognostic parameters, and novel therapeutic approaches.